Skip to main content

Table 8 Individual ambulatory care expenditures for patients with type T2DM and declining renal function in 2010 (€)

From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France

 

Pharmacy

Consultation (GP/specialist)

Nursing care

Total ambulatory care costs

Monotherapy (N = 411)

m (σ)

1,798 (2,433)

307 (252)

143 (683)

4,226 (5,369)

Increase rate vs NRF

56%

20%

0%

40%

Double therapy (N = 267)

m (σ)

1,893 (3,908)

301 (171)

210 (963)

4,159 (5,268)

Cost ratio vs mono (%)

1.094*

0.978

0.736

0.959

Increase rate vs NRF

34%

21%

38%

26%

Triple therapy (N = 78)

m (σ)

2,141 (3,056)

305 (152)

99 (504)

4,032 (4,329)

Cost ratio vs mono (%)

1.262 ***

1.029

0.903

1.031

Increase rate vs NRF

19%

17%

5%

12%

Insulin therapy (N = 267)

m (σ)

3,889 (5,363)

422 (340)

2,161 (3,638)

11,344 (11,185)

Cost ratio vs mono (%)

2.020 ***

1.230 ***

10.236 ***

2.223***

Increase rate vs NRF

47%

28%

36%

53%

  1. * 0.01 < p < 0.05; ** 0.001 < p < 0.01; *** p < 0.001.